Bioglass Market Report: Trends, Forecast and Competitive Analysis to 2035

Bioglass Market

The future of the global bioglass market looks promising with opportunities in the dental, orthopedic, and grafting biomaterial markets. The global bioglass market is expected to reach an estimated $1,340 million by 2035 from $751 million in 2027 with a CAGR of 4.3% from 2027 to 2035. The major drivers for this market are the rising demand for biocompatible materials in medical applications, the growing healthcare sector & aging population, and the increasing focus on advanced biomaterials & sustainability.

• Lucintel forecasts that, within the type category, conventional silicate glass is expected to witness the highest growth over the forecast period due to result of well documented biocompatibility and extensive clinical use.
• Within the application category, orthopedic is expected to witness the highest growth over the forecast period due to growing prevalence of bone disorders and orthopedic procedures.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to growing availability of advanced healthcare and orthopedic surgery practice.

Emerging Trends in Bioglass Market

Between 2025 and 2027, specialist dental and orthopedic applications for bioglass will decrease, while applications for regenerative medicine and precision manufacturing will increase. Clinical investments and more stringent government reviews will help create markets for bioglass. Healthcare providers are more interested in the sustainability of the materials they use. They want materials that will help in the healing process while reducing additional, invasive surgeries and waste.

• Sustainability: Manufacturers are already working to develop more sustainable ways to produce bioglass. This is proven by research that analyzes using recycled materials as feedstock instead of using new materials. Healthcare systems are likely to make sustainability a new criterion for evaluating their suppliers in the next three to five years.
• Digital Manufacturing: Research in the last few years was focused on developing bioglass that can be easily molded to fit specific shapes. Many studies in the last few years also analyzed developing bioglass with an even pore distribution. Bioglass can be molded specifically to match the shape of a patient's bone defect.
• Smart Materials: Current research is merging bioglass with several active control systems for the dissolution and biological response. Smart materials will dominate the bioglass market until dedicated therapeutic sources are developed. Manufacturers will initially focus on merging bioglass with systems to release an active substance.
• Clinical Specialization: Applications of 45S5 and S53P4 for general bone filling are also rapidly expanding into dental, spinal and chronic wound care. Research published in 2025 focused on comparing the release of ions to the healing of the patient.
• Regional Supply Diversification: After several disruptions to medical-material supply chains in 2025, buyers are now looking for alternative supplies in Europe, North America, and Asia, but qualifying new sources remains a lengthy process as many of these materials require extensive biocompatibility testing. Multi-regional manufacturing will, however, improve the continual supply and negotiation potential of supplies through 2030.

Innovation in the raw materials used for bioglass will play a smaller role in the growth of the bioglass market relative to supply/demand, clinically viable solutions and processing, and reimbursement. Suppliers that integrate control of supply with verification of results should gain market share for both dental and orthopedic devices. Regulation will slow innovation, but sustainability and digital manufacturing will improve the economics of the market through 2030. Once procurement standards mature across hospitals, we should start to see specialty applications.

Recent Developments in the Bioglass Market

By 2025, the bioglass market will shift further from dental and wound care into regenerative medicine and controlled-release systems. While growth was investment-driven in 2026, investments in capacity and clinical programs will drive growth in 2027. According to Lucintel, the market is predicted to grow; however, the limits of manufacturing and regulation will still limit market disruptions to pilot projects.

• Capacity Building: In June 2025, manufacturers will add melting and processing capacity to address a constraint in the supply of medical grade bioglass. This will enable implant and tissue engineering customers to overcome batch constraints.
• Regulatory Approvals: By September 2025, bioactive glass products received regulatory approval for use in bone and dental repair. Each approval increases confidence and reduces lead time for procurement by hospital systems.
• Strategic Partnerships: Corporate partnerships between universities and biomaterials companies for 3D-printed scaffold biomaterials were finalized in March 2026. Initially these partnerships will be competing for sales of biomaterials, however these arrangements will ensure a consistent revenue stream.
• Technology Innovations: Suppliers introduced a new line of bioglass that can be used in an injectable and additive manufacturing formats with particles of less than 100 micrometers (January 2026). The new bioglass improves manufacturing, and reduces defects, enabling broader use of bioglass in minimally invasive surgical techniques.
• Clinical Investment: In 2025, several research programs focused on clinical delivery of bioactive molecules and regeneration of soft tissues received funding. This will support price inflation of these products over the next 3-5 years.

Growth will be driven less by awareness. Instead, it will be dependent on repeatable processes for manufacturing and reimbursement. Dental will be the initial revenue stream, whereas orthopedics will be the larger growth opportunity. Focus will bring contracts in the hospital sphere. Reliable suppliers of sterile powders and degradable materials with documented clinical performance will win the contracts. Delivery systems integrators and contract manufacturing providers will be preferred. Buyers will pay less for commodity powders.

Strategic Growth Opportunities in the Bioglass Market

From 2024 to 2026, the market for bioglass will shift from specialty bone repair to broader applications in regenerative medicine and advanced dentistry. As hospitals aim for shorter recovery times, manufacturers will need to meet demands for greater traceability and sustainability of their materials. Lucintel identifies market potential for biological performance combined with manufacturing that is both scalable and clinically validated.

• Dental Regeneration: Investment in injectable and putty bioglass can serve treatments for periodontal defects, implant coatings, and hypersensitivity. January 2025 saw the public dental market for implants reach over $4 billion. In the next 3 to 5 years, dentists will purchase more products that reduce time spent in the chair and support precipitation.
• Orthopedic Trauma: High porosity scaffolds and bioglass polymer composites can be used for spinal fusion, fracture, and revision surgery. An estimated 1 million hip and knee replacement procedures are done in the US each year. Growing older and the demand for synthetic graft substitutes will encourage hospitals to move beyond traditional bone substitutes.
• Premium Bioactive Formulations: Bioglasses with strontium, copper, and zinc will be more expensive where their antimicrobial properties and faster healing are desired. In February 2025, some published research showed that certain bioactive glasses can release ions for more than four weeks. In the next 3 to 5 years, special formulations of these will likely lead to higher profits as clinicians pay for real performance, not generic powders.
• Local bioglass production and partnerships with regulatory groups may offer opportunities for expanding into India, Southeast Asia and Latin America. By 2030 medical devices are projected to be a $50 billion industry in India. Local manufacturing of dental and orthopedic devices will aid in lowering the cost of imports.
• Digital Customization: 3D printed bioglass scaffolds with pore structures specifically designed to match the surgical plans and the geometry of the defect can be manufactured. In May 2025, results of additive manufacturing research demonstrated designs with porosities in the range of 60%-100%. This technology will help shift the emphasis of the business to the development of customized implants and design software coupled with additive manufacturing.

Clinically approved products will create a demand for narrowly specific materials over broad claims. To offer supply chain services, regulatory compliance, reliable Ion release, and industrial scale will be necessary. Local production combined with digital design will provide advantages over competitors and will help offset price competition for basic bioglass powder.

Bioglass Market Drivers and Challenges

Bioglass has a growing market driven by technology, demand for healthcare, the economy, sustainability, and the changing regulations. The uses in bone and dental restoration, regeneration, wound care, and coatings broaden its market potential. There are high development costs, the need for clinical validation, substantiation for market access, and unpredictable reimbursement which limit growth. Lucintel considers innovation along with the expansion of both technology and biomaterials as major contributors. The success of companies in the marketplace in the next few years will depend on their ability to convert innovative laboratory advancements into practical and affordable products which receive acceptance in the clinical community.

The Major Driving Forces of The bioglass market Are: -

• Increasing Demand for Regenerative Healthcare: The rising demands for orthopedic, dental, and wound-care treatments have resulted in an increased interest in bioactive materials that aid tissue integration and healing. Over 800 million people reached the age of 65 in the year 2025 and the demand for bone repair along with the other aging population related challenges becomes a greater concern and will act as a market driver over the next three to five years.
• Technology-related Improvements: Better compositions of glass, the use of nanoparticles, and ion-release combined with 3D printing and other technologies, improve bioglass. 2025 was also a year of great activity in the additional suiting sector of biomedical manufacturing as customizations continued (March 2025). Better implants and materials made in bioglass along with shorter and controlled ion-release would also be market drivers as the processes become better controlled.
• Regulatory and Clinical Support: Relatively mature biomaterial standards and the strengthening of clinical evidence are building confidence in healthcare professionals and manufacturers. 2025 saw the full implementation of the European Union's Medical Device Regulation. This has strengthened the requirements for the safety of the design, clinical evaluation, and market surveillance. The next three to five years will see a preference for a strong compliance system among suppliers with validated products. This will result in a decrease in the uncertainty associated with the adoption of bioglass.
• Sustainability and Material Innovation: Bioglass can support designs of biomedical products with a lower waste footprint, waste-efficient coatings, and the replacement of some petroleum-based and/or poorly degradable materials. The European Union's packaging regulation was implemented in February 2025. This will create additional market pressure for the widespread use of more recyclable and waste-efficient materials. As hospitals, manufacturers, and investors assess a product's performance in the context of safer chemistry, lower waste, and longer product lifecycles, this driver of sustainability will influence both the design and the materials used in biomedical devices.
• Manufacturing Efficiency and Application Expansion: Recent advancements in powder production, melt processing, and sol-gel synthesis and quality control have empowered companies to produce more consistent products. In 2025, healthcare manufacturers continued a trend of increasing investments in automation to ensure continuous traceability and a lower variability in the manufacturing process (June 2025). This trend will shape the market by allowing automation to decrease the cost of each unit produced while increasing the overall volume of units produced and allowing bioglass to be implemented in new applications beyond implants for use in coatings, dental products, drug delivery and wound-care.

This Market encounters the following challenges:

• High Development and Validation Costs: Due to the extensive laboratory work, biocompatibility assessments, clinical studies and trials, and the subsequent documentation to regulatory agencies, medical device companies report longer evidence generation times to market by 2025 due to regulatory emphases on clinical data and post-market monitoring (April 2025). This trend will persist for the next three to five years and favor large, well-funded companies at the expense of smaller companies creating more innovative products.
• Manufacturing Complexity and Quality Consistency: Variations in manufacturing, such as part size, porosity, and surface modification, can affect the performance of biomaterials and reduce the desired outcomes and properties of mechanical performance. By 2025, manufacturers began to set more stringent process control criteria for advanced biomaterials to ensure the consistency of each batch (August 2025). This will impact the Market because turning a laboratory research product into a reliable commercial product requires complex instrumentation, dedicated staff, and high quality control,
• Reimbursement and Cost Sensitivity: Healthcare facilities and patients will not consider the adoption of bioglass if the policies do not consider the long-term benefits of bioglass and cheaper alternatives exist. Cost-containment measures continued in 2025, especially for elective procedures and non-essential technologies (October 2025). For the next three to five years, unless the suppliers can demonstrate better outcomes with a reduction in the costs for a healthcare provider, slow adoption due to inadequate reimbursement will persist.

The market for bioglass will continue to grow because of the increasing need for regenerative medicine, dental treatment, wound care, and personalized implants. There are many opportunities to improve technology and manufacturing to make bioglass products better and more diverse. Sustainability also makes the market more appealing to customers. However, there are several challenges including the need for more clinical validation and approval by regulatory agencies. Ending uncertainty about product consistency will help make reimbursements easier. Companies that can provide strong evidence, low-cost manufacturing, and custom-made innovations will be best positioned for growth. The market will continue to grow when researchers are able to make scientific discoveries that provide reliable and low-cost healthcare treatments that are more widely reimbursed.

List of Bioglass Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies bioglass market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bioglass market companies profiled in this report include-

• Arthrex
• Biomet
• NORAKER
• SCHOTT
• Stryker
• BonAlive Biomaterials
• British Glass Manufacturers' Confederation

Bioglass Market by Segment

The study includes a forecast for the global bioglass market by type, application, and region.

Bioglass Market by Type [Value ($M) from 2019 to 2035]:

• Conventional Silicate Glass
• Glass Ceramics
• Borate-based Glass

Bioglass Market by Application [Value ($M) from 2019 to 2035]:

• Dental
• Orthopedic
• Grafting Biomaterials
• Others

Bioglass Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Bioglass Market

The bioglass market is approaching broader, regulated, medical and dental applications with the support of public funding and emerging manufacturing options for biomaterials. With these developments, Lucintel says market expansion is likely. There are, however, some limitations on market entry that are tied to adequate reimbursement and clinical case validation.

• United States: The FDA's Quality Management System Regulation is anticipated to come into effect in February 2026. Before that, the FDA has been providing some support for the 510(k) clearances of bioactive glass bone-grafts and dental applications. Once this deadline is met by manufacturers, they will be motivated to invest in validated production, and supporting documentation and controls for their suppliers. This will be accomplished over the next three to five years.
• China: By 2025, the Chinese 14th Five-Year Plan will conclude. During this period, biomaterials and high-performance medical materials have been considered strategic or priority areas. The Chinese government is also continuing to extend centralized medical-device procurement and registration systems. By 2025, when this plan is expected to conclude, bioglass capacity in China is expected to increase. This will happen through funding of research and the development of local supply chains.
• Germany: The German market remains subject to the European Union's Medical Device Regulation. The deadline for the amended transition will be December 2027. German specialty materials producers and research organizations are focusing on clinical evidence and manufacturing that meets the required standards. This 2027 deadline will likely impact bioglass product market access especially as the evidence and quality requirements will increase.
• India: With India's ongoing National Medical Devices Policy and the Department of Pharmaceuticals' production-linked incentives, there is a continued push for domestic manufacturing, and the Indian government has set targets for reducing the medical device import dependency. The policy framework estimates a domestic medical device market size of approx. $11 billion for 2023 (February 2024). The emphasis on manufacturing will facilitate the commercialization of bioglass through local manufacturing of medical device implants and technology partnerships.
• Japan: The Pharmaceuticals and Medical Devices Agency of Japan has adopted a risk-based approach for approval and post-market surveillance of implantable biomaterials. The 2024 revision to the national health ministry's reimbursement policy, which was effective in June, is expected to influence the use of bioglass with a greater incentive for creation of clinical evidence through reimbursement and formal assessment of long-term performance of implants.

Features of the Global Bioglass Market

• Market Size Estimates: bioglass market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: bioglass market size by type, application, and region in terms of value ($B).
• Regional Analysis: bioglass market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the bioglass market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bioglass market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the bioglass market by type (conventional silicate glass, glass ceramics, and borate-based glass), application (dental, orthopedic, grafting biomaterials, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?